![Standard coagulation assays alone are not sufficient to exclude surgically relevant rivaroxaban plasma concentrations | Perioperative Medicine | Full Text Standard coagulation assays alone are not sufficient to exclude surgically relevant rivaroxaban plasma concentrations | Perioperative Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13741-019-0128-9/MediaObjects/13741_2019_128_Fig1_HTML.png)
Standard coagulation assays alone are not sufficient to exclude surgically relevant rivaroxaban plasma concentrations | Perioperative Medicine | Full Text
![Slightly elevated international normalized ratio predicts bleeding episodes in patients treated with direct oral anticoagulants - Priya Bhardwaj, Louise Breum Petersen, Tomas Sorm Binko, Jan Roland Petersen, Gitte Gleerup Fornitz, 2020 Slightly elevated international normalized ratio predicts bleeding episodes in patients treated with direct oral anticoagulants - Priya Bhardwaj, Louise Breum Petersen, Tomas Sorm Binko, Jan Roland Petersen, Gitte Gleerup Fornitz, 2020](https://journals.sagepub.com/cms/10.1177/0300060519894439/asset/images/large/10.1177_0300060519894439-fig2.jpeg)
Slightly elevated international normalized ratio predicts bleeding episodes in patients treated with direct oral anticoagulants - Priya Bhardwaj, Louise Breum Petersen, Tomas Sorm Binko, Jan Roland Petersen, Gitte Gleerup Fornitz, 2020
![Frontiers | Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban—an oral, direct Factor Xa inhibitor Frontiers | Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban—an oral, direct Factor Xa inhibitor](https://www.frontiersin.org/files/Articles/59393/fphys-05-00417-HTML/image_m/fphys-05-00417-g007.jpg)
Frontiers | Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban—an oral, direct Factor Xa inhibitor
![Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group](https://i0.wp.com/pharmaceuticalintelligence.com/wp-content/uploads/2013/09/anticoagulant.jpg)
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
![Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse](https://article.imrpress.com/journal/FBS/14/3/10.31083/j.fbs1403021/1945-0524-14-3-021/fig1.jpg)
Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse
![Slightly elevated international normalized ratio predicts bleeding episodes in patients treated with direct oral anticoagulants - Priya Bhardwaj, Louise Breum Petersen, Tomas Sorm Binko, Jan Roland Petersen, Gitte Gleerup Fornitz, 2020 Slightly elevated international normalized ratio predicts bleeding episodes in patients treated with direct oral anticoagulants - Priya Bhardwaj, Louise Breum Petersen, Tomas Sorm Binko, Jan Roland Petersen, Gitte Gleerup Fornitz, 2020](https://journals.sagepub.com/cms/10.1177/0300060519894439/asset/images/large/10.1177_0300060519894439-fig1.jpeg)
Slightly elevated international normalized ratio predicts bleeding episodes in patients treated with direct oral anticoagulants - Priya Bhardwaj, Louise Breum Petersen, Tomas Sorm Binko, Jan Roland Petersen, Gitte Gleerup Fornitz, 2020
![Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group](https://pharmaceuticalintelligence.com/wp-content/uploads/2020/07/wc-3.png)